Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics to Present at Upcoming Investor Conferences
08:05am, Tuesday, 28'th Feb 2023
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and com
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
11:19am, Thursday, 23'rd Feb 2023
Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Wednesday, 22'nd Feb 2023
Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
08:05am, Tuesday, 22'nd Nov 2022
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and com
Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript
10:14pm, Monday, 14'th Nov 2022
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations & Strategic Finance Ankit Ma
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
08:05am, Monday, 07'th Nov 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
Spero Therapeutics to Present Data at IDWeek 2022
08:05am, Wednesday, 19'th Oct 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
07:41pm, Monday, 17'th Oct 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
07:04am, Monday, 03'rd Oct 2022
Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per sha
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
06:32pm, Friday, 30'th Sep 2022
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
Hot Penny Stocks To Watch As The Stock Market Crash Continues
06:30pm, Monday, 26'th Sep 2022 PennyStocks
Hot penny stocks to add to your watch list this week. Is it time to buy?
The post Hot Penny Stocks To Watch As The Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and I
Hot Penny Stocks To Watch As The Stock Market Crash Continues
02:30pm, Monday, 26'th Sep 2022
Hot penny stocks to add to your watch list this week. Is it time to buy?
This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike
12:28pm, Monday, 26'th Sep 2022 Benzinga
UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.
Telsey Advisory Group cut NIKE, Inc. (NYSE: NKE) price target from $130 to $12
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
03:02pm, Friday, 23'rd Sep 2022 Zacks Investment Research
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
